Search

Your search keyword '"Croquette-Krokar, Marina"' showing total 17 results
Start Over Author "Croquette-Krokar, Marina"
17 results on '"Croquette-Krokar, Marina"'

7. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study

Author

Hallinan, Richard, Crettol, Séverine, Agho, Kingsley, Attia, John, Besson, Jacques, Croquette-Krokar, Marina, Hämmig, Robert, Déglon, Jean-Jacques, Byrne, Andrew, Ray, John, Somogyi, Andrew, Eap, Chin, Hallinan, Richard, Crettol, Séverine, Agho, Kingsley, Attia, John, Besson, Jacques, Croquette-Krokar, Marina, Hämmig, Robert, Déglon, Jean-Jacques, Byrne, Andrew, Ray, John, Somogyi, Andrew, and Eap, Chin

Abstract

Purpose: To assess tobacco, alcohol, cannabis and benzodiazepine use in methadone maintenance treatment (MMT) as potential sources of variability in methadone pharmacokinetics. Methods: Trough plasma (R)- and (S)-methadone concentrations were measured on 77 Australian and 74 Swiss MMT patients with no additional medications other than benzodiazepines. Simple and multiple regression analyses were performed for the primary metric, plasma methadone concentration/dose. Results: Cannabis and methadone dose were significantly associated with lower 24-h plasma (R)- and (S)-methadone concentrations/dose. The models containing these variables explained 14-16% and 17-25% of the variation in (R)- and (S)-methadone concentration/dose, respectively. Analysis of 61 patients using only CYP3A4 metabolised benzodiazepines showed this class to be associated with higher (R)-concentration/dose, which is consistent with a potential competitive inhibition of CYP3A4. Conclusion: Cannabis use and higher methadone doses in MMT could in part be a response to—or a cause of—more rapid methadone clearance. The effects of cannabis and benzodiazepines should be controlled for in future studies on methadone pharmacokinetics in MMT

Published
2018

9. Does methadone prolong QTc intervals by depleting testosterone levels?

Author

Daniell, Harry W., Ansermot, Nicolas, Albayrak, Ozgur, Schlapfer, Jurg, Wavre, Severine Crettol, Croquette-Krokar, Marina, Bourquin, Michel, Deglon, Jean-Jacques, Faouzi, Mohamed, Rey, Francois, Scherbaum, Norbert, and Eap, Chin B.

Subjects
Methadone hydrochloride -- Dosage and administration, Methadone hydrochloride -- Complications and side effects, Testosterone -- Physiological aspects, Long QT syndrome -- Risk factors, Health
Published
2010

11. Couples et abus de substances

Author

Soulignac, Rodolphe, primary, Alhadeff, Daniel, additional, Chaudet, Isabelle, additional, Congiu-Mertel, Luisella, additional, Wermeille, Nicolas, additional, Zufferey, Jean, additional, and Croquette-Krokar, Marina, additional

Published
2004
Full Text
View/download PDF

15. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment*.

Author

Crettol, Séverine, Déglon, Jean-Jacques, Besson, Jacques, Croquette-Krokar, Marina, Hämmig, Robert, Gothuey, Isabelle, Monnat, Martine, and Eap, Chin B.

Subjects
CYTOCHROME P-450, P-glycoprotein, METHADONE treatment programs, GENETIC polymorphisms, MIDAZOLAM, PHARMACOKINETICS
Abstract

Background and Objective: The in vivo implication of various cytochrome P450 (CYP) isoforms and of P-glycoprotein on methadone kinetics is unclear. We aimed to thoroughly examine the genetic factors influencing methadone kinetics and response to treatment.Methods: Genotyping for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, ABCB1, and UGT2B7 polymorphisms was performed in 245 patients undergoing methadone maintenance treatment. To assess CYP3A activity, the patients were phenotyped with midazolam.Results: The patients with lower CYP3A activity presented higher steady-state trough (R,S)-methadone plasma levels (4.3, 3.0, and 2.3 ng/mL · mg for low, medium, and high activity, respectively; P = .0002). As previously reported, CYP2B6*6/*6 carriers had significantly higher trough (S)-methadone plasma levels (P = .0001) and a trend toward higher (R)-methadone plasma levels (P = .07). CYP2D6 ultrarapid metabolizers presented lower trough (R,S)-methadone plasma levels compared with the extensive or intermediate metabolizers (2.4 and 3.3 ng/mL · mg, respectively; P = .04), whereas CYP2D6 poor metabolizer status showed no influence. ABCB1 3435TT carriers presented lower trough (R,S)-methadone plasma levels (2.7 and 3.4 ng/mL · mg for 3435TT and 3435CC carriers, respectively; P = .01). The CYP1A2, CYP2C9, CYP2C19, CYP3A5, and UGT2B7 genotypes did not influence methadone plasma levels. Only CYP2B6 displayed a stereoselectivity in its activity.Conclusion: In vivo, CYP3A4 and CYP2B6 are the major CYP isoforms involved in methadone metabolism, with CYP2D6 contributing to a minor extent. ABCB1 genetic polymorphisms also contribute slightly to the interindividual variability of methadone kinetics. The genetic polymorphisms of these 4 proteins had no influence on the response to treatment and only a small influence on the dose requirement of methadone.Clinical Pharmacology & Therapeutics (2006) 80, 668–681; doi: 10.1016/j.clpt.2006.09.012 [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

16. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study

Author

Hallinan, Richard, Crettol, Séverine, Agho, Kingsley, Attia, John, Besson, Jacques, Croquette-Krokar, Marina, Hämmig, Robert, Déglon, Jean-Jacques, Byrne, Andrew, Ray, John, Somogyi, Andrew, Eap, Chin, Hallinan, Richard, Crettol, Séverine, Agho, Kingsley, Attia, John, Besson, Jacques, Croquette-Krokar, Marina, Hämmig, Robert, Déglon, Jean-Jacques, Byrne, Andrew, Ray, John, Somogyi, Andrew, and Eap, Chin

Abstract

Purpose: To assess tobacco, alcohol, cannabis and benzodiazepine use in methadone maintenance treatment (MMT) as potential sources of variability in methadone pharmacokinetics. Methods: Trough plasma (R)- and (S)-methadone concentrations were measured on 77 Australian and 74 Swiss MMT patients with no additional medications other than benzodiazepines. Simple and multiple regression analyses were performed for the primary metric, plasma methadone concentration/dose. Results: Cannabis and methadone dose were significantly associated with lower 24-h plasma (R)- and (S)-methadone concentrations/dose. The models containing these variables explained 14-16% and 17-25% of the variation in (R)- and (S)-methadone concentration/dose, respectively. Analysis of 61 patients using only CYP3A4 metabolised benzodiazepines showed this class to be associated with higher (R)-concentration/dose, which is consistent with a potential competitive inhibition of CYP3A4. Conclusion: Cannabis use and higher methadone doses in MMT could in part be a response to—or a cause of—more rapid methadone clearance. The effects of cannabis and benzodiazepines should be controlled for in future studies on methadone pharmacokinetics in MMT

17. [New Drugs: Ectasy and Gamma-Hydroxy-Butyrate (GHB)].

Author

Feldman N and Croquette-Krokar M

Subjects
Adolescent, Adult, Female, Humans, Male, Substance-Related Disorders epidemiology, Hallucinogens adverse effects, Illicit Drugs, Mental Disorders chemically induced, N-Methyl-3,4-methylenedioxyamphetamine adverse effects, Serotonin Syndrome chemically induced, Sodium Oxybate adverse effects, Substance-Related Disorders complications
Abstract

For several years the "raves" and "tecno" parties are accompanied of a growing consumption of such substances as Ecstasy and Gamma-Hidroxi-Butirato (GHB). In this article, their authors describe the secondary and toxic effects of those drugs. These data should alert about the risk of considering this new way of substance abuse as a banal fact.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results